Basking Biosciences is developing a novel first-line therapy (BB-031) targeting von Willebrand Factor (vWF), along with a direct acting reversal agent (BB-025) to immediately neutralize the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. BB-031 is being evaluated in patients with acute ischemic stroke (AIS) in the RAISE trial, a two-part Phase 2 study assessing the safety and preliminary efficacy of the investigational drug candidate. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.
Company Details
- Employees
- 11
- Founded
- 2019
- Address
- 1275 Kinnear Road, Columbus,oh 43212,united States
- Industry
- Biotechnology
- Keywords
- pharma, neurology, biotech, cardiovascular.
- HQ
- Columbus, OH
Basking Biosciences Inc Questions
Basking Biosciences Inc's website is http://www.baskingbiosciences.com
Basking Biosciences Inc's LinkedIn profile is https://www.linkedin.com/company/basking-biosciences-inc
Basking Biosciences Inc has
11 employees.
View email and phone details for 11
employees at Basking Biosciences Inc.
Basking Biosciences Inc's industry is
Biotechnology
Basking Biosciences Inc's top competitors are
858 Therapeutics,
Capacity Bio,
Dem Biopharma, Inc.,
Locanabio, Inc.,
Clarametyx Biosciences,
Superluminal Medicines Inc.,
Profluent,
Convelo Therapeutics, Inc,
Cirsium Biosciences,
Switch Therapeutics.
Basking Biosciences Inc's categories are Biotechnology
Basking Biosciences Inc's founding year is 2019
